Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard H Chapman

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Journal of Managed Care & Specialty Pharmacy|May 1, 2019
Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?Richard H Chapman, Varun Kumar
Applied Health Economics and Health Policy|March 20, 2020
Modeling Medicaid and Medicare Savings from Reduced Poverty and Disability to Promote Investment in Mental Health and Substance Use Interventions in the USANathaniel Z Counts, Paul Gionfriddo, Richard H Chapman
BMC Cardiovascular Disorders|June 23, 2010
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrolleesRichard H Chapman, Jason Yeaw, Craig S Roberts
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?Steven D Pearson, Daniel A Ollendorf, Richard H Chapman
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 14, 2018
Evaluating and Valuing Drugs for Rare Conditions: No Easy AnswersDaniel A Ollendorf, Richard H Chapman, Steven D Pearson
Pharmacoeconomics|September 9, 2025
HTA Evidence in Rare Diseases: Just Rare or Also Special?Anirban Basu, Simu K Thomas, Richard H Chapman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 9, 2020
Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating MutationKael Wherry, Ian Williamson, Richard H Chapman, et al.
Current Medical Research and Opinion|March 19, 2008
Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemiaHarold E Bays, Richard H Chapman, Kathleen M Fox, et al.
BMC Cardiovascular Disorders|March 18, 2011
Determining initial and follow-up costs of cardiovascular events in a US managed care populationRichard H Chapman, Larry Z Liu, Prafulla G Girase, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 13, 2021
Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost OffsetsRichard H Chapman, Varun M Kumar, Melanie D Whittington, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Journal of Managed Care & Specialty Pharmacy|May 1, 2019
Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?Richard H Chapman, Varun Kumar
Applied Health Economics and Health Policy|March 20, 2020
Modeling Medicaid and Medicare Savings from Reduced Poverty and Disability to Promote Investment in Mental Health and Substance Use Interventions in the USANathaniel Z Counts, Paul Gionfriddo, Richard H Chapman
BMC Cardiovascular Disorders|June 23, 2010
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrolleesRichard H Chapman, Jason Yeaw, Craig S Roberts
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?Steven D Pearson, Daniel A Ollendorf, Richard H Chapman
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 14, 2018
Evaluating and Valuing Drugs for Rare Conditions: No Easy AnswersDaniel A Ollendorf, Richard H Chapman, Steven D Pearson
Pharmacoeconomics|September 9, 2025
HTA Evidence in Rare Diseases: Just Rare or Also Special?Anirban Basu, Simu K Thomas, Richard H Chapman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 9, 2020
Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating MutationKael Wherry, Ian Williamson, Richard H Chapman, et al.
Current Medical Research and Opinion|March 19, 2008
Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemiaHarold E Bays, Richard H Chapman, Kathleen M Fox, et al.
BMC Cardiovascular Disorders|March 18, 2011
Determining initial and follow-up costs of cardiovascular events in a US managed care populationRichard H Chapman, Larry Z Liu, Prafulla G Girase, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 13, 2021
Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost OffsetsRichard H Chapman, Varun M Kumar, Melanie D Whittington, et al.
Pageof 6